A detailed history of Aqr Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 137,171 shares of PTGX stock, worth $5.39 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
137,171
Previous 25,055 447.48%
Holding current value
$5.39 Million
Previous $868,000 610.14%
% of portfolio
0.01%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $3.78 Million - $5.31 Million
112,116 Added 447.48%
137,171 $6.16 Million
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $1.38 Million - $1.95 Million
-55,952 Reduced 69.07%
25,055 $868,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $1.56 Million - $2.3 Million
71,665 Added 767.13%
81,007 $2.34 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $15,792 - $26,346
-1,124 Reduced 10.74%
9,342 $214,000
Q3 2023

Nov 14, 2023

SELL
$16.68 - $23.66 $10,892 - $15,449
-653 Reduced 5.87%
10,466 $174,000
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $200,364 - $326,453
11,119 New
11,119 $307,000
Q4 2022

Feb 14, 2023

SELL
$7.36 - $11.17 $542,564 - $823,430
-73,718 Reduced 64.28%
40,970 $446,000
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $901,447 - $1.34 Million
114,688 New
114,688 $967,000
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $354,231 - $547,586
-15,177 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $467,195 - $983,150
-26,500 Reduced 63.58%
15,177 $519,000
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $195,143 - $748,778
15,069 Added 56.63%
41,677 $739,000
Q2 2021

Aug 16, 2021

SELL
$25.57 - $44.88 $96,629 - $169,601
-3,779 Reduced 12.44%
26,608 $1.19 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $132,455 - $216,928
6,964 Added 29.73%
30,387 $787,000
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $11,519 - $15,655
623 Added 2.73%
23,423 $472,000
Q3 2020

Nov 16, 2020

BUY
$15.19 - $22.4 $346,332 - $510,719
22,800 New
22,800 $446,000
Q2 2020

Aug 17, 2020

SELL
$6.19 - $18.84 $70,237 - $213,777
-11,347 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$5.4 - $9.22 $61,236 - $104,554
-11,340 Reduced 49.98%
11,347 $80,000
Q3 2019

Nov 14, 2019

BUY
$9.41 - $16.56 $213,484 - $375,696
22,687 New
22,687 $272,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.